Halogen Containing Or Process Utilizing Halogen Or Halogen Containing Compound Patents (Class 546/258)
-
Patent number: 7939548Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.Type: GrantFiled: July 31, 2007Date of Patent: May 10, 2011Assignee: Cytokinetics, Inc.Inventors: Pu-Ping Lu, Xiangping Qian, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
-
Publication number: 20110092544Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein each W and Y is independently CH2, O, C(?O), S(?O)n, NR8 or a direct bond; R4 is H, halogen, cyano, hydroxy, C1-C2 alkyl, C1-C2 haloalkyl, C2 alkenyl, C2 haloalkenyl or C2 alkynyl; m is an integer selected from 0, 1, 2, 3, 4 and 5; and R1, R2, R3, R5, R8 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.Type: ApplicationFiled: June 18, 2009Publication date: April 21, 2011Applicant: E.I. DU PONT DE nemours and companyInventor: Bruce Lawrence Finkelstein
-
Patent number: 7923558Abstract: The invention relates to a method for obtaining pure tetrahydrocannabinol from reaction mixtures containing tetrahydrocannabinol compounds or from raw products containing tetrahydrocannabinol compounds. According to said method, the tetrahydrocannabinol compounds in the reaction mixture or in the raw product are converted into crystallisable derivatives, preferably using a suitable solvent, said derivatives are then crystallised and isolated, and the pure tetrahydrocannabinol compounds are then obtained from the crystallised derivatives. The invention also related to the use of compounds produced in this way for the production of a medicament for human therapy, and to the medicaments thus produced.Type: GrantFiled: July 19, 2004Date of Patent: April 12, 2011Assignee: Cilag Ltd.Inventors: Enver Arslantas, Ulrich Weigl
-
Publication number: 20110002027Abstract: An electrochromic material including at least one compound represented by Chemical Formulas 1 to 3: wherein Z1 to Z3 are each independently selected from a substituted or unsubstituted C6 to C30 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group, a substituted or unsubstituted C3 to C30 cycloalkylene group or a combination thereof, R1 to R3 are each independently selected from a single bond, a substituted or unsubstituted C1 to C30 alkylene group, a substituted or unsubstituted C3 to C30 cycloalkylene group, a substituted or unsubstituted C6 to C30 arylene group, a substituted or unsubstituted C2 to C30 heteroarylene group or a combination thereof.Type: ApplicationFiled: February 16, 2010Publication date: January 6, 2011Applicant: Samsung Electronics Co., Ltd.Inventors: Rupasree Ragini Das, Chang-Ho Noh, Ji-Min Lee, Seog-Jin Jeon
-
Publication number: 20100324052Abstract: The invention relates to novel piperidine carboxylic acid amide derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of these novel compounds, pharmaceutical compositions comprising such compounds and especially the use of such compounds as inhibitors of renin.Type: ApplicationFiled: August 12, 2010Publication date: December 23, 2010Inventors: Olivier Bezencon, Christoph Boss, Daniel Bur, Austin Chih-Yu Chen, Olivier Corminboeuf, Daniel Dube, Walter Fischli, Corinna Grisostomi, Lubos Remen, Sylvia Richard-Bildstein, Thierry Sifferlen, Michel Therien, Thomas Weller
-
Publication number: 20100317670Abstract: The present invention discloses a compound of formula: where Ar1, Ar2, X, Z1, Z2, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Pyridylene Compound”); compositions comprising an effective amount of a Pyridylene Compound; and methods for treating or preventing pain or other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Pyridylene Compound.Type: ApplicationFiled: July 21, 2010Publication date: December 16, 2010Applicant: PURDUE PHARMA L.P.Inventor: QUN SUN
-
Patent number: 7851701Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.Type: GrantFiled: July 5, 2002Date of Patent: December 14, 2010Assignee: Nippon Kayaku Kabushiki KaishaInventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
-
Publication number: 20100311736Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.Type: ApplicationFiled: October 22, 2008Publication date: December 9, 2010Inventors: Nicholas D. Adams, Michael Gerard Darcy, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Kenneth Allen Newlander, Xin Peng, Lance H. Ridgers
-
Publication number: 20100298221Abstract: The present invention relates to novel 2-phenoxy-6-phenyl- and 2-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis and heart failure.Type: ApplicationFiled: August 30, 2007Publication date: November 25, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Heinrich Meier, Peter kolkhof, Axel Kretschmer, Arounarith Tuch, Lars Barfacker, Yolanda Cancho Grande
-
Patent number: 7829341Abstract: The invention relates to a class of glucose-responsive, polyviologen boronic acid quenchers that may be used in combination with fluophores to achieve real-time measurement of glucose levels in vivo.Type: GrantFiled: July 11, 2008Date of Patent: November 9, 2010Assignee: Glumetrics, Inc.Inventors: Soya Gamsey, Ritchie A. Wessling
-
Patent number: 7812251Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.Type: GrantFiled: October 15, 2004Date of Patent: October 12, 2010Assignee: Sharp Kabushiki KaishaInventors: Ashraful Islam, Liyuan Han, Atsushi Fukui
-
Publication number: 20100197652Abstract: The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: August 7, 2008Publication date: August 5, 2010Inventors: Jeffrey M. Bergman, Paul J. Coleman, Mark E. Fraley, Swati P. Mercer, Thomas S. Reger, Anthony J. Roecker, Justin T. Steen
-
Publication number: 20100133480Abstract: A compound containing at least two pyridinium derivatives in its molecular structure and being in a reduced form thereof may be used as a CNT n-doping material. The compound may donate electrons spontaneously to CNTs to n-dope the CNTs, while being oxidized into its stable state. An n-doped CNT that is doped with the CNT n-doping material may maintain a stable n-doped state for a long time without being dedoped even in the air and/or water. Further, the n-doped state may be easily controlled when using the CNT n-doping material.Type: ApplicationFiled: May 7, 2009Publication date: June 3, 2010Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Hyeon Jin SHIN, Young HEE LEE, Jaeyoung CHOI, Seonmi YOON, Soo Min KIM
-
Publication number: 20100130552Abstract: A compound of Formula: (I) or a pharmaceutically acceptable derivative thereof, where Ar1, Ar2, X, R3, and m are as disclosed herein. Compounds of Formulae (I)-(V) and pharmaceutically acceptable derivatives thereof; compositions comprising an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof; and methods for treating or preventing pain, UI, an ulcer, IBD, or IBS in an animal comprising administering to an animal in need thereof an effective amount of a compound of Formulae (I)-(V) or a pharmaceutically acceptable derivative thereof are disclosed herein.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Inventor: Laykea Tafesse
-
Publication number: 20100063056Abstract: The present invention is directed to bipyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: February 29, 2008Publication date: March 11, 2010Inventors: Paul J. Coleman, Swati P. Mercer, Anthony J. Roecker
-
Patent number: 7662821Abstract: The invention relates to tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents.Type: GrantFiled: October 12, 2004Date of Patent: February 16, 2010Assignee: Bayer Schering Pharma AGInventors: Hartmut Rehwinkel, Stefan Baeurle, Markus Berger, Norbert Schmees, Heike Schaecke, Konrad Krolikiewicz, Anne Mengel, Duy Nguyen, Stefan Jaroch, Werner Skuballa
-
Publication number: 20100035931Abstract: The present invention is directed to tripyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Inventors: Paul J. Coleman, Swati P. Mereer, Thomas S. Reger, Anthony J. Rocker
-
Patent number: 7632950Abstract: The present invention provides pyridine derivatives useful as intermediates of drugs and agricultural chemicals, electrophotographic receptors, dyes and so on. More specifically, the invention relates to novel pyridyltetrahydropyridines and novel pyridylpiperidines, and further to a method of manufacturing pyridine derivatives through reaction between bipyridine derivatives and benzyl halide or benzyloxycarbonyl halide and subsequent reduction of the resultant reaction products with the aid of palladium catalysts, platinum catalysts, ruthenium catalysts or rhodium catalysts.Type: GrantFiled: August 18, 2004Date of Patent: December 15, 2009Assignee: Fujifilm Finechemicals Co., LtdInventors: Hirokazu Kuwabara, Takayuki Sonoda, Hiromitsu Saitoh, Hidehiro Arai
-
Publication number: 20090298872Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorder associated with the activation of steroid hormone nuclear receptors.Type: ApplicationFiled: December 13, 2005Publication date: December 3, 2009Applicant: IRM LLCInventors: Pierre-Yves Michellys, Wei Pei, John Wityak
-
Patent number: 7612065Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.Type: GrantFiled: March 28, 2007Date of Patent: November 3, 2009Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeremy Green, Susanne Wilke, Francesco Salituro, Edmund Harrington, Jingrong Cao, Guy Bemis, Huai Gao
-
Publication number: 20090253907Abstract: A phosphine compound represented by general formula (1) wherein R? and R? independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R? and R? are joined together to form with the phosphorous atom a carbon-phosphorous monocycle including at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cps is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. These phosphines can be used as ligands in catalytic reactions.Type: ApplicationFiled: August 14, 2007Publication date: October 8, 2009Inventors: Herbert Plenio, Christoph Fleckenstein, Renat Kadyrov, Juan Almena, Axel Monsees, Thomas Riermeier
-
Publication number: 20090176796Abstract: The invention relates to compounds of formula IA? and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA? or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA? or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: April 25, 2008Publication date: July 9, 2009Applicant: Purdue Pharma L. P.Inventor: Laykea Tafesse
-
Publication number: 20090170867Abstract: The invention relates to compounds of formula IA? and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA? or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA? or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: April 25, 2008Publication date: July 2, 2009Applicant: Shionogi & Co., Ltd.Inventor: Noriyuki Kurose
-
Publication number: 20090170868Abstract: The invention relates to compounds of formula IA and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: April 25, 2008Publication date: July 2, 2009Applicant: Purdue Pharma L. P.Inventor: Laykea Tafesse
-
Publication number: 20090111957Abstract: The present invention also relates a metal complex complexing with the fluoro-ponytailed bipyridine derivatives, which is represented by the general formula (2): and each Rf is the same or different and represents a fluoro-alkyl group having from 3 to 11 carbon atoms, preferably a perfluoro-alkyl group having from 9 to 11 carbon atoms; X? represents a halogenide such as fluoride, bromide, chloride, or iodide; and M represents a metal selected from the group consisting of Mo, Cr, Re, Ru, Fe, Rh, Ni, Pd, and Cu.Type: ApplicationFiled: October 31, 2007Publication date: April 30, 2009Applicant: NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGYInventors: Norman Lu, Tsung-Chi Chen
-
Patent number: 7517994Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.Type: GrantFiled: May 18, 2005Date of Patent: April 14, 2009Assignee: Array Biopharma Inc.Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
-
Publication number: 20090082570Abstract: Provided is a method of manufacturing a bipyridinium compound denoted by general formula (A). In general formula (A), Ar1 and Ar2 each independently denote an optionally substituted (hetero)aryl group, R3 and R4 each independently denote a substituent that may form a ring with a pyridine ring to which the substituent substitutes, m3 and m4 each independently denote an integer ranging from 0 to 4, X denotes a halogen atom or RSO3, and R denotes an optionally substituted aryl group or alkyl group. The method can manufacture a 4,4?-bipyridinium compound under mild reaction conditions in an integrated manner without separation of intermediates.Type: ApplicationFiled: September 17, 2008Publication date: March 26, 2009Applicant: FUJIFILM CorporationInventors: Kazumi Nii, Toshinao Ukai, Kazufumi Omura
-
Publication number: 20090076087Abstract: The present application describes deuterium-enriched etoricoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 11, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090044345Abstract: The present invention relates to the use, as oxidation catalysts, of metal complex compounds having tetradentate ligands of formula (2) wherein all substitutents have the meanings as defined in Claim 1. The present invention relates also to formulations comprising such metal complex compounds, to novel metal complex compounds and to novel ligands.Type: ApplicationFiled: February 6, 2006Publication date: February 19, 2009Inventors: Gunther Schlingloff, Kishor Ramachandra Nivalkar, Torsten Wieprecht, Marie-Josee Dubs, Nicole End
-
Publication number: 20090023763Abstract: New antagonists of the A2B adenosine receptor represented by formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of the A2B adenosine receptor.Type: ApplicationFiled: April 12, 2005Publication date: January 22, 2009Inventors: Bernat Vidal Juan, Paul Robert Eastwood, Jacob Gonzalez Rodriguez
-
Publication number: 20080287461Abstract: 4-pyridone derivatives of Formula (1) and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.Type: ApplicationFiled: March 2, 2006Publication date: November 20, 2008Inventors: Jose Maria Fiandor Roman, Jose Maria Bueno Calderon, Araceli Mallo Rubio
-
Patent number: 7435743Abstract: Pyrimidine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.Type: GrantFiled: September 30, 2005Date of Patent: October 14, 2008Assignee: Bayer AktiengesellschaftInventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshiro, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuiyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy B. Lowinger, Karl B. Ziegelbauer, Kinji Fuchikami, Hiroshi Komura
-
Patent number: 7385095Abstract: The present invention provides an indene derivatives having a new structure and an organic light-emitting diode using the same. The organic light-emitting diode according to the present invention shows improved effects in efficiency, driving voltage and stability.Type: GrantFiled: October 19, 2006Date of Patent: June 10, 2008Assignee: LG Chem, Ltd.Inventors: Dae Woong Lee, Jae Soon Bae, Dong Hoon Lee, Kong Kyeom Kim
-
Publication number: 20080132545Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.Type: ApplicationFiled: July 31, 2007Publication date: June 5, 2008Inventors: Pu-Ping Lu, Xiangping Qian, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans
-
Publication number: 20080070931Abstract: The present invention relates to compounds of the formula wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.Type: ApplicationFiled: August 29, 2007Publication date: March 20, 2008Inventors: Paul Hebeisen, Stephan Roever
-
Patent number: 7301029Abstract: The invention provides a bipyridine derivative useful as an intermediate for pharmaceutical products, agricultural chemicals, electrophotographic photosensitive materials, dyes and the like, which is a bipyridine derivative represented by the general formula (I) and a salt thereof: wherein R1 represents an alkyl group with 2 to 20 carbon atoms having a substituent, substituted or unsubstituted aminomethyl group, trifluoromethyl group, substituted or unsubstituted thiomethyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkoxy group, substituted or unsubstituted aryloxy group, substituted carbonyl group, substituted sulfonyl group, unsubstituted or monosubstituted carbamoyl group, unsubstituted or monosubstituted sulfamoyl group, substituted or unsubstituted thiol group, unsubstituted or monosubstituted amino group, substituted carbonylamino group, substituted or unsubstituted ureido group, nitro group, cyano group, formyl group or an equivalent thereof, iodine atom or fluType: GrantFiled: August 12, 2004Date of Patent: November 27, 2007Assignee: Fujifilm Finechemicals Co., Ltd.Inventors: Hirokazu Kuwabara, Takayuki Sonoda, Hiromitsu Saitoh, Hidehiro Arai
-
Patent number: 7241795Abstract: The present invention relates to novel 2,5-bis{[alkyl (or aryl) imino]aminophenyl}furans and thiophenes of the general formula in which R1, R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups; R5 is H, alkyl or aryl; R6 is H, alkyl, aryl, or NR7R8, in which R7 and R8 are each independently selected from the group consisting of H, alkyl and aryl; and X is O, S or NR9, in which R9 is H or alkyl, and to the use of such compounds.Type: GrantFiled: March 2, 2004Date of Patent: July 10, 2007Assignees: The University of North Carolina at Chapel Hill, Georgia State University Research Foundation, Inc., Duke UniversityInventors: David W. Boykin, Richard R. Tidwell, W. David Wilson, John R. Perfect, Chad F. Stephens
-
Patent number: 7064212Abstract: Electrochromic salts. Electrochromic salts of dicationic viologens such as methyl viologen and benzyl viologen associated with anions selected from bis(trifluoromethylsulfonyl)imide, bis(perfluoroethylsulfonyl)imide, and tris(trifluoromethylsulfonyl)methide are produced by metathesis with the corresponding viologen dihalide. They are highly soluble in molten quarternary ammonium salts and together with a suitable reductant provide electrolyte solutions that are used in electrochromic windows.Type: GrantFiled: June 20, 2002Date of Patent: June 20, 2006Assignee: The Regents of the University of CaliforniaInventors: Anthony K. Burrell, Benjamin P. Warner, T. Mark McClesky
-
Patent number: 7060715Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: August 11, 2004Date of Patent: June 13, 2006Assignee: Merck Frosst Canada Ltd.Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
-
Patent number: 6987112Abstract: The present invention is directed to compounds represented by Formula (1); wherein A, R, X, Y and n are as defined in the description, the salts thereof, and insecticide/acaricide compositions characterized by comprising one or more of said compounds and/or said salts as the active ingredients.Type: GrantFiled: November 1, 2001Date of Patent: January 17, 2006Assignee: Nippon Soda Co., Ltd.Inventors: Yasushi Shibata, Renpei Hatano, Takao Iwasa, Satoru Makita, Daisuke Hanai, Masao Yamaguchi, Naomi Ichikawa
-
Patent number: 6921768Abstract: The invention relates to cerium compounds having general formulas (I) Rni+Yin? and (II) Rb+Yb+ and their application as medicaments in the prophylaxis and/or treatment of cancer diseases.Type: GrantFiled: February 6, 2004Date of Patent: July 26, 2005Assignee: Faustus Forschungs Cie. Translational Cancer Research GmbHInventor: Bernhard Keppler
-
Publication number: 20040267021Abstract: The present invention provides processes for preparing terpyridine compounds. In particular, the present invention provides a process for the preparation of a C1-C4-alkyl pyridine-2-carboxylate compound, a 1,5-bis(2-pyridyl)pentane-1,3,5-trione compound, and a 2,6-bis(2-pyridyl)-4(1H)pyridinone compound.Type: ApplicationFiled: April 14, 2004Publication date: December 30, 2004Applicant: BASF AktiengesellschaftInventors: Ralph Lunkwitz, Gunther Pabst, Gunter Scherr
-
Patent number: 6812346Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: March 24, 2003Date of Patent: November 2, 2004Assignee: Merck Frosst Canada and Co.Inventors: Daniel Dube, Rejean Fortin, Richard Friesen
-
Patent number: 6784296Abstract: The present invention provides a process for preparing a terpyridine compound of the formula I by obtaining a C1-C4-alkyl pyridine-2-carboxylate derivative by acid hydrolysis of a 2-cyanopyridine derivative by means of an anhydrous inorganic acid or its anhydride in the presence of water and a C1-C4-alkanol, with an equimolar amount of water being added to the 2-cyanopyridine derivative prior to addition of the anhydrous inorganic acid or its anhydride, subsequently condensing the resultant C1-C4-alkyl pyridine-2-carboxylate derivative with acetone in an aprotic solvent in the presence of a base, then reacting the obtained 1,5-bis(2-pyridyl)pentane-1,3,5-trione derivative with ammonia or ammonium salts (NH4)qY with removal of the water of reaction formed by employing a C1-C4-alkanol as an entrainer, and finally chlorinating the resultant 2,6-bis(2-pyridyl)-4(1H)pyridinone derivative in the presence of phosphorus oxide chloride.Type: GrantFiled: April 30, 2002Date of Patent: August 31, 2004Assignee: BASF AktiengesellschaftInventors: Ralph Lunkwitz, Gunther Pabst, Günter Scherr
-
Patent number: 6605625Abstract: Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations including their use as antiarrhythmic active compounds, for example, for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutters. Compounds of the invention include compounds of the formula I in which: A1, A2, A3, A4, A5, A6, A7 and A8 independently of one another are chosen from nitrogen, CH and CR(5), at least four of these groups being CH, and wherein all other variables are as defined here.Type: GrantFiled: November 29, 2001Date of Patent: August 12, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Stefan Peukert, Joachim Brendel, Horst Hemmerle, Heinz-Werner Kleemann
-
Patent number: 6596736Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: October 30, 2001Date of Patent: July 22, 2003Assignee: Merck & Co., Inc.Inventors: Daniel Dube, Rejean Fortin, Richard Friesen, Zhaoyin Wang, Jacques Yves Gauthier
-
Patent number: 6562824Abstract: This invention relates to novel dihydropyridine soft drugs of the formula &PHgr;OOR1, where &PHgr; is a dihydropyridine moiety. These compounds are useful as calcium channel antagonists with cardiovascular, antiasthmatic and antibroncho-constriction activity. Use of such soft drug analogs permits the administration of greater doses of the claimed dihydropyridine compounds without intolerable systemic effects. Thus, this invention also provides pharmaceutical compositions, as well as methods, for preventing and treating disorders such as hypersensitivity, allergy, asthma, bronchospasim, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorders, gastrointestinal motility disorders and cardiovascular disorders, while avoiding unwanted systemic effects.Type: GrantFiled: May 2, 2001Date of Patent: May 13, 2003Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: John H. Dodd, James L. Bullington, Daniel A. Hall, James R. Henry, Kenneth C. Rupert
-
Publication number: 20020198238Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: 1Type: ApplicationFiled: June 26, 2002Publication date: December 26, 2002Applicant: Merck & Co., Inc.Inventor: Louis S. Crocker
-
Patent number: 6489344Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.Type: GrantFiled: June 18, 1999Date of Patent: December 3, 2002Assignee: Chiron CorporationInventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
-
Patent number: 6489483Abstract: A process for producing a 2-pyridylpyridine derivative usable as an intermediate for medicines or agricultural chemicals is provided, which does not require expensive special catalysts and special equipment, which does not cause environmental problems, and which can be conducted on an industiral scale. The process comprises reacting an acetyl-substituted pyridine derivative with a 3-amino acrolein, then reacting the reaction product with ammonia or an ammonium salt.Type: GrantFiled: December 13, 2001Date of Patent: December 3, 2002Assignee: Sankio Chemical Co., Ltd.Inventors: Hirokazu Suda, Ken Umihara